0001140361-23-035731.txt : 20230721
0001140361-23-035731.hdr.sgml : 20230721
20230721211120
ACCESSION NUMBER: 0001140361-23-035731
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230719
FILED AS OF DATE: 20230721
DATE AS OF CHANGE: 20230721
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Helsel Dave
CENTRAL INDEX KEY: 0001543753
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50761
FILM NUMBER: 231103605
MAIL ADDRESS:
STREET 1: 400 WOOD ROAD
CITY: BRAINTREE
STATE: MA
ZIP: 02184
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANGIODYNAMICS INC
CENTRAL INDEX KEY: 0001275187
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 113146460
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0531
BUSINESS ADDRESS:
STREET 1: 14 PLAZA DRIVE
CITY: LATHAM
STATE: NY
ZIP: 12110
BUSINESS PHONE: 5187981215
MAIL ADDRESS:
STREET 1: 14 PLAZA DRIVE
CITY: LATHAM
STATE: NY
ZIP: 12110
4
1
form4.xml
X0508
4
2023-07-19
0001275187
ANGIODYNAMICS INC
ANGO
0001543753
Helsel Dave
14 PLAZA DRIVE
LATHAM
NY
12110
true
SVP Global Operations and R&D
false
Common Stock
2023-07-19
4
A
0
10789
0
A
28986
D
Performance Right
2023-07-19
4
A
0
21578
0
A
Common Stock
21578
21578
D
Non-Qualified Stock Option (right to buy)
8.92
2023-07-19
4
A
0
22329
0
A
2024-07-19
2033-07-19
Common Stock
22329
22329
D
The acquisition of 10,789 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 10,789 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 19, 2024, such that 25% of the restricted stock units will vest on each of July 19, 2024, 2025, 2026 and 2027.
Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.
These stock options vest in four equal annual installments beginning on July 19, 2024, such that 25% of the options will vest on each of July 19, 2024, 2025, 2026 and 2027.
/s/ Stephen A. Trowbridge, Attorney in Fact
2023-07-21